Menu

Multiple Sclerosis: Subtypes, Symptoms, and Treatment: Publications and Documents

Summary

The Disabled World list of publications on Multiple Sclerosis offers a comprehensive collection of articles and papers covering various aspects of the disease. These resources explore MS subtypes, such as relapsing-remitting and primary progressive, as well as common symptoms like fatigue, vision problems, and mobility issues. The list includes peer-reviewed research on diagnostic techniques, including MRI scans and spinal fluid analysis, along with detailed information on treatment options ranging from disease-modifying therapies to symptom management strategies. Many articles provide practical advice for daily living with MS, discussing topics like exercise, nutrition, and cognitive rehabilitation. This diverse array of publications serves as a valuable resource for individuals with MS, their caregivers, healthcare professionals, and researchers, offering insights into the latest developments in MS care and support.

Searching the Database

The data table below lists items that may have been updated or revised, but the table defaults to sorting by descending publication date; you can search and sort by clicking column headers (JavaScript required). Items in this category are also distributed via our Multiple Sclerosis: Subtypes, Symptoms, and Treatment RSS feed.

Multiple Sclerosis: Subtypes, Symptoms, and Treatment: Publications and Resources (49 Items)
Title and DescriptionEdPublish
Revised

Clinical trial of Autologous Hematopoietic Stem Cell Transplantation versus Best Available Therapy for Multiple Sclerosis (BEAT-MS) begins enrollment.


Those with MS who feel stigmatized are more likely to have depression, having a support system of friends and family and a sense of autonomy may help reduce the harmful effects of stigma..


Research proposals will invite researchers to establish a Canadian cohort of people living with MS to study progression in the disease.


Multiple Sclerosis study brings us closer to understanding which older adults with MS may be at higher risk of getting worse.

Phase III CLARITY study data revealed significant reduction in brain atrophy in patients on short course of investigational Cladribine Tablets over two years.


Study finds the age at which symptoms of multiple sclerosis (MS) first start is strongly linked to latitude.

Stem cell treatment improves established disability in patients with progressive MS and shows there is hope future treatment is possible.


Summary of significant 2015 multiple sclerosis research progress and initiatives from The National Multiple Sclerosis Society.


New research could lead to the development of new types of drugs to treat Multiple Sclerosis (MS).


Follow-up of girls and women who received human papillomavirus (HPV) vaccination found no increased risk for these disorders.

Research scientists are one step closer to creating a viable cell replacement therapy for multiple sclerosis from a patients own cells.


Case discovered that her inability to walk and other MS symptoms were triggered by her dental mercury fillings.


Health Canada approved FAMPYRA on February 10, 2012 for the symptomatic improvement of walking in adult MS patients with walking disability.


Minimally invasive endovascular treatment for CCSVI may produce significant improvement in physical and mental quality of life in individuals with MS.


Diagnostic breakthrough in multiple sclerosis reveals cause may be bio-mechanical related to earlier trauma to the neck resulting in obstruction of cerebrospinal fluid flow.


Molecular mechanism could bring about the development of new treatments for Multiple Sclerosis (MS).

Endovascular therapy or angioplasty is the nonsurgical procedure of threading a thin tube into a vein or artery to open blocked or narrowed blood vessels.

There is epidemiological evidence that some herpes viruses may contribute to multiple sclerosis (MS) occurrence.


Viagra drastically reduces multiple sclerosis symptoms in animal models with the disease.

Scientists develop compound that effectively halts progression of multiple sclerosis (MS), the discovery also holds promise for other autoimmune disorders.


By noting the presence of markers in a diagnostic test, researchers predict whether patients will suffer faster onset of disability and counsel them to help ease anxiety.


Gilenya delayed progression of disability both for patients who were previously treated for their MS and for patients who had not received prior treatment.

Multiple sclerosis is a seriously disabling autoimmune disease that can lead to disturbance or loss of sensory function voluntary movement vision and bladder control.


People living with MS need more information to make the best choices for the benefit of their health.

Multiple sclerosis is a life altering disease that affects each person in a unique and different way.


Gilenya (fingolimod) is the first disease modifying oral therapy developed for the relapsing-remitting form of multiple sclerosis (MS).


Fumaric acid salts used against severe psoriasis may also have a favorable effect on Multiple Sclerosis as a result of their TH2 polarizing mechanisms.


Damage to a particular area of the brain and a consequent reduction in noradrenaline are associated with multiple sclerosis.

Peer-reviewed research reveals histamine's role in modulating immune response and reducing MS symptoms, pointing to new autoimmune disease therapies.



Multiple Sclerosis (MS) Progress was made toward finding ways to restore function and improving quality of life through exercise meditation rehabilitation and medications.


Damage caused by multiple sclerosis could be reversed by activating stem cells that can repair injury in the central nervous system.

The complexity of the immune system and nervous system turn Neuroimmunology into one of the most exciting fields of modern biomedicine.

Phase II Study with Ocrelizumab Shows Significant Reduction in Disease Activity for Multiple Sclerosis Patients.


Albuterol sulfate used to treat bronchospasm in asthma may decrease interleukin-12 levels.


Meeting of leading North American experts in multiple sclerosis (MS) to identify research priorities for Canada.

Trial to test bone marrow stem cell therapy with patients with multiple sclerosis shown to have possible benefits for treatment of the disease.


Society of Interventional Radiology position statement supporting clinical research into CCSVI and endovascular treatments for multiple sclerosis patients.



Hard To Treat Diseases - Scientists report results that are encouraging for the future of Multiple Sclerosis Treatment.

FDA approves Ampyra (dalfampridine) drug to improve walking in patients with multiple sclerosis (MS).


Major trial of oral drug Cladribine has shown it significantly reduces relapse and deterioration of multiple sclerosis (MS).


Several papers published this year provided more evidence that starting on MS therapies early after disease onset, or even before a definite diagnosis, can pay off later by delaying disease progression.


People with multiple sclerosis who have relapses within five years of onset have more severe disability in the short term.

Research study could overturn the prevailing wisdom on the cause of multiple sclerosis (MS).


Study finds two genes associated with good central nervous system repair in multiple sclerosis.

Virus responsible for rare brain disease found to be reactivated in multiple-sclerosis patients being treated with natalizumab.


A new experimental treatment for multiple sclerosis (MS) completely reverses the devastating autoimmune disorder.

Antegren for multiple sclerosis is a monoclonal antibody that is given by monthly infusion into a vein.


Low-dose naltrexone shows promise in halting MS progression and improving quality of life, but patients struggle to access the treatment due to lack of clinical trials.



Experimental drug fampridine 4-aminopyridine improves walking ability in some individuals with multiple sclerosis MS.

Key: the first check mark indicates the publication carries an editor's note; the second indicates a footnote.

Note: Disabled World compiles disability-related publications as a resource. Inclusion does not imply endorsement by Disabled-World.com. To submit disability-related articles and peer-reviewed manuscripts and papers, ensure submissions comply with our guidelines. For questions, please contact us.

Back to Multiple Sclerosis: Subtypes, Symptoms, and Treatment Index.

Share This Information

Permalink:

Database of <a href="https://www.disabled-world.com/health/autoimmunediseases/ms-2/">Multiple Sclerosis: Subtypes, Symptoms, and Treatment documents, papers, and peer reviewed publications</a> - Disabled World (DW).

While we strive to provide accurate, up-to-date information, our content is for general informational purposes only. Please consult qualified professionals for advice specific to your situation.